about
Dose optimisation of antibiotics in children: application of pharmacokinetics/pharmacodynamics in paediatricsPostantibiotic effects of antituberculosis agents alone and in combinationA novel approach to pharmacodynamic assessment of antimicrobial agents: new insights to dosing regimen designMathematical model of plasmid-mediated resistance to ceftiofur in commensal enteric Escherichia coli of cattleRapid, serial, non-invasive assessment of drug efficacy in mice with autoluminescent Mycobacterium ulcerans infectionThe Lysis of Pathogenic Escherichia coli by Bacteriophages Releases Less Endotoxin Than by β-LactamsIn vitro antimicrobial effects of various combinations of penicillin and clindamycin against four strains of Streptococcus pyogenes.Phenotypic tolerance: antibiotic enrichment of noninherited resistance in bacterial populationsTwo pharmacodynamic models for assessing the efficacy of amoxicillin-clavulanate against experimental respiratory tract infections caused by strains of Streptococcus pneumoniaePharmacodynamic comparisons of levofloxacin, ciprofloxacin, and ampicillin against Streptococcus pneumoniae in an in vitro model of infection.Pharmacokinetics of tobramycin in adults with cystic fibrosis: implications for once-daily administrationOptimization of meropenem minimum concentration/MIC ratio to suppress in vitro resistance of Pseudomonas aeruginosaEx vivo pharmacodynamics of amoxicillin-clavulanate against beta-lactamase-producing Escherichia coli in a yucatan miniature pig model that mimics human pharmacokinetics.Pharmacokinetics and pharmacodynamics of aerosolized antibacterial agents in chronically infected cystic fibrosis patients.Pharmacodynamic evaluation of the intracellular activities of antibiotics against Staphylococcus aureus in a model of THP-1 macrophages.Pharmacokinetics and pharmacodynamics of cefepime in patients with various degrees of renal function.Pharmacodynamics of ceftazidime administered as continuous infusion or intermittent bolus alone and in combination with single daily-dose amikacin against Pseudomonas aeruginosa in an in vitro infection model.Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected gram-negative infectionsAlteration of postantibiotic effect during one dosing interval of tobramycin, simulated in an in vitro pharmacokinetic model.Pharmacodynamic evaluation of a new glycopeptide, LY333328, and in vitro activity against Staphylococcus aureus and Enterococcus faeciumVersatility of aminoglycosides and prospects for their future.Continuous infusion of beta-lactam antibioticsIn vitro postantibiotic effects following multiple exposures of cefotaxime, ciprofloxacin, and gentamicin against Escherichia coli in pooled human cerebrospinal fluid and Mueller-Hinton broth.Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model.Optimal times above MICs of ceftibuten and cefaclor in experimental intra-abdominal infectionsEffect of pooled human cerebrospinal fluid on the postantibiotic effects of cefotaxime, ciprofloxacin, and gentamicin against Escherichia coli.Setting and revising antibacterial susceptibility breakpoints.Real-time monitoring of intracellular Staphylococcus aureus replicationContinuous beta-lactam infusion in critically ill patients: the clinical evidenced-Methionine reduces tobramycin-induced ototoxicity without antimicrobial interference in animal models.In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures.Functional relationship between bacterial cell density and the efficacy of antibiotics.Rhesus θ-defensin-1 (RTD-1) exhibits in vitro and in vivo activity against cystic fibrosis strains of Pseudomonas aeruginosa.Pharmacodynamic functions: a multiparameter approach to the design of antibiotic treatment regimens.Pharmacokinetics and pharmacodynamics of intravenous levofloxacin at 750 milligrams and various doses of metronidazole in healthy adult subjects.Tobramycin administered by the TOBI(®) Podhaler(®) for persons with cystic fibrosis: a review.In vitro activity of trovafloxacin against Bacteroides fragilis in mixed culture with either Escherichia coli or a vancomycin- resistant strain of Enterococcus faecium determined by an anaerobic time-kill technique.Comparisons between antimicrobial pharmacodynamic indices and bacterial killing as described by using the Zhi modelExperience with a once-daily aminoglycoside program administered to 2,184 adult patients.Novel approach to characterization of combined pharmacodynamic effects of antimicrobial agents.
P2860
Q26853629-9EDC47CE-CC98-4A71-890B-73A53DE516A0Q28364143-77628814-B419-4A7D-AD0F-0F2B9AA3C1BDQ28476705-8EC8E369-3FD6-4491-97C8-B18CB8D4604FQ28483752-CFEBF5FD-258F-4218-BCDB-48BABC129ED7Q28537749-C14A6440-5C9E-49CE-AA1A-4ED9AF2C765CQ33696025-F505B54A-763B-43F2-9CEA-48206463F3D2Q33696181-B299F1EE-9D2C-4984-B6C0-FE2121BFB809Q33722011-00C006C4-3363-4669-A4CC-09A0D741B773Q33975832-B254963B-6927-46E8-8641-676CC2FDC642Q33976517-9D48017A-356C-425C-8C6F-4B8353889539Q33979054-6E2BFE69-78BC-4187-8FD2-D4032C488BE7Q34228382-6DC3658C-B17D-46E1-84D9-B7A93027B813Q34252545-6640F354-84BF-4BC3-8663-BD308D30D85AQ34297656-8251643A-63DB-426C-A746-8C50DD51222CQ34509728-FDF3DAD8-529D-4370-A9F5-92646B9D8ACCQ35013708-F1EF442B-C634-4984-A348-ECCFB4C30F98Q35117352-D75B3E1E-4C59-4E79-85BF-3FE60E9A966DQ35123123-8A32545E-C574-42AF-8C01-4E08F044C2E6Q35123348-0116339E-6B5A-4CF7-954D-6E3058A06F10Q35136634-06F1BA04-3D2E-499C-AEC5-31ABC6648694Q35176271-0E7392A0-6F70-49BA-B464-E7AC3E9B06C6Q35656806-432006ED-2A8A-40AD-87D9-B9AB0F6C758BQ35815249-72254737-E154-4CA8-A147-868ED317A41CQ35820123-84ECEBD4-CC25-4617-833B-3D1F367BF0F9Q35820708-E2349DFF-1824-4BF6-A34C-D251117F7FF9Q35836760-3928C9EE-3A16-4F6B-9C32-874FE6644392Q35913176-0D744965-1889-4523-AC48-386F23230125Q36233447-B31D1142-7A2B-4A8A-8C65-DCF59088B74CQ36329228-D9B0FCB7-5D28-40FB-8CE5-D25F8455EABBQ36446781-B0D7E831-D7C2-404F-BE3B-4089D2EBD9FFQ36744871-9B95F1F4-10FC-48C3-87C2-CC7ECB32F491Q37124158-D0C1BD73-3A40-4546-AE26-2D2374B77321Q37223605-4E1AEBC5-9273-4EF9-9483-6E458C4C1069Q37568933-EF938C4B-5470-4ECD-8408-C07774CA9143Q37625098-64576BEC-662D-4C18-9824-F265C663C983Q38037076-6737FEF1-99F1-4274-A5D8-A2455DCB9261Q39475998-1CF71296-58CF-45E6-BE2D-5551419DA1FDQ39558024-52556424-C27A-4A66-89DA-E0CB7BFA638AQ39779327-74ADEE5C-501A-42B8-9F86-405B21C1FB46Q40291140-7020DFF4-1ED8-4A32-8065-5E188B975BAF
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 1990
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Killing and regrowth of bacteria in vitro: a review.
@en
Killing and regrowth of bacteria in vitro: a review.
@nl
type
label
Killing and regrowth of bacteria in vitro: a review.
@en
Killing and regrowth of bacteria in vitro: a review.
@nl
prefLabel
Killing and regrowth of bacteria in vitro: a review.
@en
Killing and regrowth of bacteria in vitro: a review.
@nl
P1476
Killing and regrowth of bacteria in vitro: a review
@en
P2093
P577
1990-01-01T00:00:00Z